- Our Doctors
- Dr Xue-Yan Jiang
Dr Xue Yan Jiang
Clinical Oncologist. BSc, MSc (Biomed), (MBBS)
Languages spoken
English, Chinese (Mandarin)
Expert in
Prostate cancer, bladder cancer, kidney cancers
Overview
Centres
Specialises in
Dr Xue Yan Jiang is a Consultant Clinical Oncologist specialising in urological cancers. She graduated with merits from Newcastle University in 2008. She also holds a BSc and a MSc (Biomed) from Northumbria University.
She was appointed as a Consultant since 2020 at the Northern Centre for Cancer Care (NCCC), Freeman Hospital in Newcastle NHS Foundation Trust Hospitals. She has additional leadership roles in clinical governance as well quality and safety.
Dr Jiang’s clinical practice involves looking after patients with urological cancers (prostate, kidney and bladder). Her research interests include radiotherapy, imaging, bone health and biomarkers.
Her other interests are teaching and education. She is both a clinical and an educational supervisor to resident doctors, pharmacists and Advanced Clinical Practioners (ACPs).
Clinical Oncology is the best and the only specialty which delivers consistent cutting edge patient centred holistic care. Everything we learnt in medical school are used –from anatomy to pathology , surgery to medicine, not to forget physics! - Dr Xue Yan Jiang
Expertise and interests
- Bladder Cancer
- Kidney cancer
- Prostate cancer
- Radiotherapy
- Imaging
- Bone health
- Biomarkers
- Education
- Clinical trials
Professional memberships
- Member of Royal College of Physicians (Edinburgh) (MRCP)
- Fellow of Royal College of Radiologist (FRCR) UK
Publications & affiliations
- High-dose palliative radiotherapy in metastatic castrate-resistant prostate cancer – is it worthwhile? A single-centre outcome. (September 2022Clinical Oncology 34:e6)
- High dose palliative radiotherapy in bladder cancer - A single centre experience from the UK. (August 2021Radiotherapy and Oncology 161:S1152-S1153)
- Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life. (Clinical Oncology 32 (2020) e177ee187)
- Prostate Ultra hypnofraction – Rising to Challenges Presents Opportunities in the COVID-19 Era. (Clinical Oncology 33 (2021) e90)
- Optimising bone health management in advanced prostate cancer: A comparative cohort study. (February 2023 Journal of Clinical Oncology 41(6_suppl):133-133)